Cyclooxygenase-2–specific inhibitors: are they safe?
- 8 January 2001
- journal article
- review article
- Published by Elsevier in American Journal Of Medicine
- Vol. 110 (1), S46-S49
- https://doi.org/10.1016/s0002-9343(00)00650-1
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.JAMA, 1999
- Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid ArthritisJAMA, 1999
- Immunolocalization of cyclooxygenase‐2 in the macula densa of human elderlyFEBS Letters, 1999
- Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?JAMA, 1999
- Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjectsClinical Pharmacology & Therapeutics, 1999
- Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysisProceedings of the National Academy of Sciences, 1999
- Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implicationsAmerican Journal Of Medicine, 1999
- Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX- inhibiting Therapies (SELECT) trial in osteoarthritisRheumatology, 1998
- Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment [published erratum appears in Br J Rheumatol 1998 Oct;37(10):1142]Rheumatology, 1998
- Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory DrugsAnnals of Internal Medicine, 1995